Business Combination - Purchase consideration (Details) - LymphaTech $ in Thousands |
Feb. 17, 2026
USD ($)
|
|---|---|
| Asset Acquisition | |
| Cash consideration payments to LymphaTech stockholders | $ 7,230 |
| Estimated fair value of contingent consideration | 4,863 |
| Total purchase consideration | $ 12,093 |
| X | ||||||||||
- Definition Amount of contingent consideration recognized as part of consideration transferred in a business combination. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|